Ipilimumab vs Pacritinib Citrate
Ipilimumab vs Pacritinib Citrate: Overview
This comparison examines the pharmacological differences between Ipilimumab and Pacritinib Citrate.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Pharmacokinetics
Half-life: Ipilimumab — 14.7 days.
Chemical Properties
Type: Ipilimumab — Antibody; Pacritinib Citrate — Small molecule.